⚙ PAGE STYLES + THANK-YOU SCRIPT — hidden on the live page. Edit fonts/colors in each widget; edit shared rules here.
Free Provider Briefing
10 Key Takeaways from the James LaValle Webinar,
The Current State of Peptides
What prescribing providers need to know after the FDA’s Pharmacy Compounding Advisory Committee (PCAC) recommended six peptides for 503A compounding eligibility.
A 3-page PDF you can read in five minutes, from Southend Pharmacy’s educational webinar with Dr. James LaValle. Educational content only — compounded medications are not FDA-approved.
Why this matters
The vote made headlines.
The details decide what you can actually do.
- BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax were recommended for the Category 1 bulk substances list.
- DSIP was reviewed alongside them and did not get a recommendation — inclusion is peptide by peptide.
- A committee recommendation is not a final rule; FDA and HHS rulemaking is still pending.
- Sourcing and testing matter as much as the molecule: identity, contaminants, FDA-registered API suppliers.
Download the briefing
Get the 10 takeaways
before the final rule lands.
Enter your details and we’ll send the PDF straight to your inbox.
- Which six peptides were recommended — and the one that wasn't
- Why this is a recommendation, not a rule, and what still has to happen
- What the committee actually weighed (it isn't a clinical trial standard)
- What separates a compliant 503A product from gray-market product
- By submitting you agree to receive educational emails from Southend Pharmacy. Unsubscribe anytime. We never share your information.
About the speaker
“Inclusion is evaluated peptide by peptide, not as a category.”
Dr. James LaValle
B.S.Pharm, CCN, MT, DHM, DHPh
Guest speaker at Southend Pharmacy’s educational provider webinar, The Current State of Peptides.
Our Coverage
Southend Pharmacy Supports Providers Across 40+ States And Growing
Interactive map, updated real-time and monitored by our team during expansion
Active state
Not Active State
40
States Covered
55K
SQ FT Facility
Centrally located Houston, TX
280M
Patients Reachable
*Total population in covered states
76%
US Population
Check your inbox
Your briefing is on its way.
Or grab it right here.
If it isn’t there in a couple of minutes, check your spam or promotions folder.
Want the full webinar with Dr. LaValle?